Renal artery stenosis
Conditions
Interventions
In the control group, renal angiography stenosis was 70%-90%:Drug treatment
Intervention group (FFR evaluation group), renal angiography stenosis 50%-69%:Renal angiography and FFR measurements, renal artery stent release
In the control group, renal angiography stenosis was 50%-69%:Drug treatment
Intervention group (FFR evaluation group) renal angiography stenosis 70%-90%:Renal angiography and FFR measurements, renal artery stent release
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 18-80; 2.Patients with atherosclerotic renal artery stenosis; 3.Renal artery angiography confirmed that renal artery stenosis is 50%-90%; 4.Patients willing to receive medical treatment and sign informed consent form; 5.Patients with hypertension (including severe hypertension, malignant hypertension, refractory hypertension, worsening hypertension or drug intolerance); 6.Patients with abnormal renal function and short-term decline in renal function on the affected side; Note: Among the above standards, conditions 1 to 4 must be met, and at least one of conditions 5 and 6 must be satisfied.
Exclusion criteria
Exclusion criteria: 1.Long diameter of the kidney =2+); 3.CT or MR shows that there are a large number of renal parenchymal areas without perfusion; 4.Glomerular filtration rate (GFR) =3.0 mg/dL; 6.Intrarenal artery resistance index >=0.8; 7.Congenital malformation of renal artery is not suitable for interventional treatment; 8.Severe cardiac insufficiency, contrast allergies, active infection, malignant tumors or life expectancy is less than the study period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Flow Reserve Fraction (FFR);Renal angiography stenosis degree;Related indicators of renal function, including single-renal glomerular filtration rate (GFR), improvement of single-renal blood flow perfusion, improvement of serum creatinine, cystatin, and 24-hour;24-hour dynamic blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Follow-up blood pressure; | — |
Countries
China
Contacts
Public ContactDehui Qian
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed